1207539-57-8

Basic information

• Product Name: N-methyl-7-(4-morpholinophenyl)-[1,6]naphthyridin-5-yl-amine
• Synonyms: N-methyl-7-(4-morpholinophenyl)-[1,6]naphthyridin-5-yl-amine
• CAS NO: 1207539-57-8
• Molecular Weight: 320.394
• Mol File: 1207539-57-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-methyl-7-(4-morpholinophenyl)-[1,6]naphthyridin-5-yl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-7-(4-morpholinophenyl)-[1,6]naphthyridin-5-yl-amine(1207539-57-8)
• EPA Substance Registry System: N-methyl-7-(4-morpholinophenyl)-[1,6]naphthyridin-5-yl-amine(1207539-57-8)

Safety Data

• Hazardous Substances Data: 1207539-57-8(Hazardous Substances Data)

Upstream product

• 10282-31-2 4-morpholinobenzonitrile 
• 74-89-5 methylamine 
• 3222-56-8 2-methylnicotinic acid 

Relevant articles and documents

SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 denotes a group A selected from among —O—R3, —NR3R4, —CR3R4R5, -(ethyne)-R3, —S—R3, —SO—R3 and SO2—R3 or R1 denotes a group B selected from among C6-10-aryl,five- to ten-membered, mono- or bicyclic heteroaryl with 1-3 heteroatoms selected independently of one another from among N, O and S; while this heteroaryl is linked to the structure according to formula 1 via either a C atom or an N atom,three- to ten-membered, mono- or bicyclic, saturated or partially saturated heterocyclic group with 1-3 heteroatoms selected independently of one another from among N, O and S, while this heterocyclic group is linked to the structure according to formula 1 via either a C atom or an N atom, and 5- to 11-membered spiro group which may optionally contain 1, 2 or 3 heteroatoms selected independently of one another from among N, O and S, while this spiro group is linked to the structure according to formula 1 via either a C atom or an N atom, while this group B may optionally be substituted as described in claim 1 and wherein R2 is and R3, R4, R5, R6, R6′, R7, R8, R9, R10, V, n and m may have the meanings given in claim 1, as well as pharmaceutical compositions containing these compounds.